NKG2A + NK cell activity against CLL cells was significantly increased by selinexor at all concentrations tested (50–2000 nM) as measured by both degranulation (mean 5.8% at 0 nM rising to 10.6% at 500 nM, P < 0.001) and IFNγ expression (mean 0.5% at 0 nM rising to 1.5% at 500 nM, P < 0.001) (Fig. 3B–E). This evidence concerns the gene KLRC1 and B-cell chronic lymphocytic leukemia.